Skip to main content
- Press releases
Merck Serono announces the creation of Asceneuron, the third Spin-Off company from its entrepreneur Partnership Program. Asceneuron will develop Merck Serono’s research programs in the area of Alzheimer’s disease.

Merck Serono, a division of Merck, Darmstadt, Germany, announced today the creation of Asceneuron, a spin-off company resulting from its Entrepreneur Partnership Program (EPP) launched in April 2012. Asceneuron will focus on the development of therapies for the treatment of Alzheimer’s disease and Tau protein-related pathologies, by advancing Merck Serono’s preclinical programs targeting these conditions towards clinical testing as rapidly as possible. Merck Serono will invest € 5 million as seed funding. Merck Serono Ventures will manage the investment and will be represented on the company’s board of directors.

Download the PDF